Download PDF
Thromb Haemost 2022; 122(01): 113-122
DOI: 10.1055/a-1522-4131
Blood Cells, Inflammation and Infection

Extracellular Vesicles and Citrullinated Histone H3 in Coronavirus Disease 2019 Patients

Ludwig Traby
1   Department of Medicine I, Medical University of Vienna, Vienna, Austria
,
Marietta Kollars
1   Department of Medicine I, Medical University of Vienna, Vienna, Austria
,
Manuel Kussmann
1   Department of Medicine I, Medical University of Vienna, Vienna, Austria
,
Matthias Karer 
1   Department of Medicine I, Medical University of Vienna, Vienna, Austria
,
Hana Šinkovec
2   Section for Clinical Biometrics, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria
,
Elisabeth Lobmeyr
1   Department of Medicine I, Medical University of Vienna, Vienna, Austria
,
Alexander Hermann 
1   Department of Medicine I, Medical University of Vienna, Vienna, Austria
,
Thomas Staudinger
1   Department of Medicine I, Medical University of Vienna, Vienna, Austria
,
Peter Schellongowski
1   Department of Medicine I, Medical University of Vienna, Vienna, Austria
,
Bernhard Rössler
3   Medical Simulation and Emergency Management Research Group, Department of Anesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Vienna, Austria
,
Heinz Burgmann
1   Department of Medicine I, Medical University of Vienna, Vienna, Austria
,
Paul A. Kyrle
1   Department of Medicine I, Medical University of Vienna, Vienna, Austria
,
Sabine Eichinger
1   Department of Medicine I, Medical University of Vienna, Vienna, Austria
› Author Affiliations Funding This work was supported by the Medizinisch-Wissenschaftliche Fonds des Bürgermeisters der Bundeshauptstadt Wien (grant number: COVID041).
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objectives Pulmonary thrombus formation is a hallmark of coronavirus disease 2019 (COVID-19). A dysregulated immune response culminating in thromboinflammation has been described, but the pathomechanisms remain unclear.

Methods We studied 41 adult COVID-19 patients with positive results on reverse-transcriptase polymerase-chain-reaction assays and 37 sex- and age-matched healthy controls. Number and surface characteristics of extracellular vesicles (EVs) and citrullinated histone H3 levels were determined in plasma upon inclusion by flow cytometry and immunoassay.

Results In total, 20 patients had severe and 21 nonsevere disease. The number of EV (median [25th, 75th percentile]) was significantly higher in patients compared with controls (658.8 [353.2, 876.6] vs. 435.5 [332.5, 585.3], geometric mean ratio [95% confidence intervals]: 2.6 [1.9, 3.6]; p < 0.001). Patients exhibited significantly higher numbers of EVs derived from platelets, endothelial cells, leukocytes, or neutrophils than controls. EVs from alveolar-macrophages and alveolar-epithelial cells were detectable in plasma and were significantly higher in patients. Intercellular adhesion molecule-1-positive EV levels were higher in patients, while no difference between tissue factor-positive and angiotensin-converting enzyme-positive EV was seen between both groups. Levels of EV did not differ between patients with severe and nonsevere COVID-19. Citrullinated histone H3 levels (ng/mL, median [25th, 75th percentile]) were higher in patients than in controls (1.42 [0.6, 3.4] vs. 0.31 [0.1, 0.6], geometric mean ratio: 4.44 [2.6, 7.7]; p < 0.001), and were significantly lower in patients with nonsevere disease compared with those with severe disease.

Conclusion EV and citrullinated histone H3 are associated with COVID-19 and could provide information regarding pathophysiology of the disease.

Keywords

COVID-19 - extracellular vesicles - NETs - coagulation activation - ARDS - immunothrombosis - citrullinated histone H 3

Supplementary Material



Publication History

Received: 16 April 2021

Accepted: 31 May 2021

Accepted Manuscript online:
02 June 2021

Article published online:
11 July 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 World Health Organization. COVID-19 Weekly epidemiological update - 23 February 2021. World Health Organization. Published 2021. Accessed March 01, 2021 at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
    PubMedGoogle Scholar
  • 2 Guan WJ, Ni ZY, Hu Y. et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382 (18) 1708-1720
    CrossrefPubMedGoogle Scholar
  • 3 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506
    CrossrefPubMedGoogle Scholar
  • 4 Bourgonje AR, Abdulle AE, Timens W. et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol 2020; 251 (03) 228-248
    CrossrefPubMedGoogle Scholar
  • 5 Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020; 368 (6490): 473-474
    CrossrefPubMedGoogle Scholar
  • 6 McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020; 19 (06) 102537
    CrossrefPubMedGoogle Scholar
  • 7 Webb BJ, Peltan ID, Jensen P. et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol 2020; 2 (12) e754-e763
    CrossrefPubMedGoogle Scholar
  • 8 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395 (10229): 1033-1034
    CrossrefPubMedGoogle Scholar
  • 9 Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 2020; 20 (06) 355-362
    CrossrefPubMedGoogle Scholar
  • 10 Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020; 7 (06) e438-e440
    CrossrefPubMedGoogle Scholar
  • 11 Ackermann M, Verleden SE, Kuehnel M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020; 383 (02) 120-128
    CrossrefPubMedGoogle Scholar
  • 12 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054-1062
    CrossrefPubMedGoogle Scholar
  • 13 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18 (04) 844-847
    CrossrefPubMedGoogle Scholar
  • 14 Klok FA, Kruip MJHA, van der Meer NJM. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-147
    CrossrefPubMedGoogle Scholar
  • 15 Chirinos JA, Heresi GA, Velasquez H. et al. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol 2005; 45 (09) 1467-1471
    CrossrefPubMedGoogle Scholar
  • 16 Nieuwland R, Berckmans RJ, McGregor S. et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95 (03) 930-935
    CrossrefPubMedGoogle Scholar
  • 17 Coumans FAW, Brisson AR, Buzas EI. et al. Methodological guidelines to study extracellular vesicles. Circ Res 2017; 120 (10) 1632-1648
    CrossrefPubMedGoogle Scholar
  • 18 Owens III AP, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011; 108 (10) 1284-1297
    CrossrefPubMedGoogle Scholar
  • 19 Hron G, Kollars M, Weber H. et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97 (01) 119-123
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Vallier L, Cointe S, Lacroix R. et al. Microparticles and fibrinolysis. Semin Thromb Hemost 2017; 43 (02) 129-134
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 EL Andaloussi S, Mäger I, Breakefield XO, Wood MJ. S ELA. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 2013; 12 (05) 347-357
    CrossrefPubMedGoogle Scholar
  • 22 Zuo Y, Yalavarthi S, Shi H. et al. Neutrophil extracellular traps in COVID-19. JCI Insight 2020; 5 (11) e138999
    PubMedGoogle Scholar
  • 23 Middleton EA, He XY, Denorme F. et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 2020; 136 (10) 1169-1179
    CrossrefPubMedGoogle Scholar
  • 24 Martinod K, Demers M, Fuchs TA. et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci U S A 2013; 110 (21) 8674-8679
    CrossrefPubMedGoogle Scholar
  • 25 World Health Organization. Clinical management of COVID-19, interim guidance. Available at: . Published 2020. Updated May 27, 2020. Accessed March 01, 2021
    PubMedGoogle Scholar
  • 26 Cappellano G, Raineri D, Rolla R. et al. Circulating platelet-derived extracellular vesicles are a hallmark of SARS-Cov-2 infection. Cells 2021; 10 (01) 85
    CrossrefPubMedGoogle Scholar
  • 27 Canzano P, Brambilla M, Porro B. et al. Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients. JACC Basic Transl Sci 2021; 6 (03) 202-218
    CrossrefPubMedGoogle Scholar
  • 28 Nomura S, Shimizu M. Clinical significance of procoagulant microparticles. J Intensive Care 2015; 3 (01) 2
    CrossrefPubMedGoogle Scholar
  • 29 Puhm F, Boilard E, Machlus KR. Platelet extracellular vesicles: beyond the blood. Arterioscler Thromb Vasc Biol 2021; 41 (01) 87-96
    PubMedGoogle Scholar
  • 30 Ridger VC, Boulanger CM, Angelillo-Scherrer A. et al; Position Paper of the European Society of Cardiology (ESC) Working Group on Atherosclerosis and Vascular Biology. Microvesicles in vascular homeostasis and diseases. Thromb Haemost 2017; 117 (07) 1296-1316
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Abid Hussein MN, Böing AN, Biró E. et al. Phospholipid composition of in vitro endothelial microparticles and their in vivo thrombogenic properties. Thromb Res 2008; 121 (06) 865-871
    CrossrefPubMedGoogle Scholar
  • 32 Aras O, Shet A, Bach RR. et al. Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood 2004; 103 (12) 4545-4553
    CrossrefPubMedGoogle Scholar
  • 33 Sarkar A, Mitra S, Mehta S, Raices R, Wewers MD. Monocyte derived microvesicles deliver a cell death message via encapsulated caspase-1. PLoS One 2009; 4 (09) e7140
    CrossrefPubMedGoogle Scholar
  • 34 Chironi G, Simon A, Hugel B. et al. Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol 2006; 26 (12) 2775-2780
    CrossrefPubMedGoogle Scholar
  • 35 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181 (02) 271.e8-280.e8
    CrossrefPubMedGoogle Scholar
  • 36 Takei Y, Yamada M, Saito K. et al. Increase in circulating ACE-positive endothelial microparticles during acute lung injury. Eur Respir J 2019; 54 (04) 1801188
    CrossrefPubMedGoogle Scholar
  • 37 Danilov SM, Gavrilyuk VD, Franke FE. et al. Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. Am J Physiol Lung Cell Mol Physiol 2001; 280 (06) L1335-L1347
    CrossrefPubMedGoogle Scholar
  • 38 Hosseinkhani B, van den Akker NMS, Molin DGM, Michiels L. (Sub)populations of extracellular vesicles released by TNF-α -triggered human endothelial cells promote vascular inflammation and monocyte migration. J Extracell Vesicles 2020; 9 (01) 1801153
    CrossrefPubMedGoogle Scholar
  • 39 Rautou PE, Leroyer AS, Ramkhelawon B. et al. Microparticles from human atherosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transendothelial migration. Circ Res 2011; 108 (03) 335-343
    CrossrefPubMedGoogle Scholar
  • 40 Rosell A, Havervall S, von Meijenfeldt F. et al. Patients with COVID-19 have elevated levels of circulating extracellular vesicle tissue factor activity that is associated with severity and mortality-brief report. Arterioscler Thromb Vasc Biol 2021; 41 (02) 878-882
    CrossrefPubMedGoogle Scholar
  • 41 Ng H, Havervall S, Rosell A. et al. Circulating markers of neutrophil extracellular traps are of prognostic value in patients with COVID-19. Arterioscler Thromb Vasc Biol 2021; 41 (02) 988-994
    CrossrefPubMedGoogle Scholar
  • 42 Veras FP, Pontelli MC, Silva CM. et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J Exp Med 2020; 217 (12) e20201129
    CrossrefPubMedGoogle Scholar
  • 43 Lacroix R, Judicone C, Poncelet P. et al. Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. J Thromb Haemost 2012; 10 (03) 437-446
    CrossrefPubMedGoogle Scholar